-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BMO Capital Maintains Market Perform on CytomX Therapeutics, Raises Price Target to $3.2

Benzinga · 01/06/2023 08:10
BMO Capital analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Market Perform and raises the price target from $2.6 to $3.2.